A multicenter, double-blind, randomized, placebo controlled trial of a neurokinin-1 receptor antagonist for overactive bladder

Journal of Urology

Volumn 184, Issue 2, 2010, Pages 616-622

  Frenkl, Tara L ^a   Zhu, Haiyuan ^a   Reiss, Theodore ^a   Seltzer, Olga ^a   Rosenberg, Elizabeth ^a   Green, Stuart ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

muscarinic antagonists; neurokinin 1; overactive; receptors; tolterodine; urinary bladder

Indexed keywords

NEUROKININ 1 RECEPTOR ANTAGONIST; SERLOPITANT; TOLTERODINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RELEASE; DRUG TOLERABILITY; FEMALE; HUMAN; INCONTINENCE; MAJOR CLINICAL STUDY; MALE; MICTURITION; MULTICENTER STUDY; OVERACTIVE BLADDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; URGE INCONTINENCE; XEROSTOMIA;

BENZHYDRYL COMPOUNDS; CRESOLS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; ISOINDOLES; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PHENYLPROPANOLAMINE; RECEPTORS, NEUROKININ-1; URINARY BLADDER, OVERACTIVE;

EID: 77955466939     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2010.03.147     Document Type: Article

References (27)

1. P. Abrams, L. Cardozo, and M. Fall The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society Neurourol Urodyn 21 2002 167
2. I. Milsom, P. Abrams, and L. Cardozo How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study BJU Int 87 2001 760
3. W.F. Stewart, J.B. Van Rooyen, and G.W. Cundiff Prevalence and burden of overactive bladder in the United States World J Urol 20 2003 327
4. D.E. Irwin, I. Milsom, and Z. Kopp Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries BJU Int 97 2006 96
5. S. Serels The wet patient: understanding patients with overactive bladder and incontinence Curr Med Res Opin 20 2004 791
6. K.E. Andersson, C.R. Chapple, and L. Cardozo Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence Curr Opin Urol 19 2009 380
7. P. Abrams, and K.E. Andersson Muscarinic receptor antagonists for overactive bladder BJU Int 100 2007 987
8. 2009 P.I. Tolterodine Tolterodine tartrate extended release capsules 2009 Pfizer Inc New York, New York revised 2008
9. C.J. Mussap, D.P. Geraghty, and E. Burcher Tachykinin receptors: a radioligand binding perspective J Neurochem 60 1993 1987
10. L. Caberlotto, Y.L. Hurd, and P. Murdock Neurokinin 1 receptor and relative abundance of the short and long isoforms in the human brain Eur J Neurosci 17 2003 1736
11. M. Otsuka, and K. Yoshioka Neurotransmitter functions of mammalian tachykinins Physiol Rev 73 1993 229
12. M. Abdel-Gawad, S.B. Dion, and M.M. Elhilali Evidence of a peripheral role of neurokinins in detrusor hyperreflexia: a further study of selective tachykinin antagonists in chronic spinal injured rats J Urol 165 2001 1739
13. T. Quinn, C. Collins, and A.W. Baird Mechanisms of neurokinin A- and substance P-induced contractions in rat detrusor smooth muscle in vitro BJU Int 94 2004 651
14. A. Lecci, S. Giuliani, and P. Santicioli Involvement of spinal tachykinin NK1 and NK2 receptors in detrusor hyperreflexia during chemical cystitis in anaesthetized rats Eur J Pharmacol 259 1994 129
15. K.H. Moore, S.A. Gilpin, and J.S. Dixon Increase in presumptive sensory nerves of the urinary bladder in idiopathic detrusor instability Br J Urol 70 1992 370
16. T. Doi, I. Kamo, and S. Imai Effects of TAK-637, a tachykinin receptor antagonist, on the micturition reflex in guinea pigs Eur J Pharmacol 395 2000 241
17. K.E. Andersson Tachykinins: role in detrusor overactivity? Eur Urol 49 2006 423
18. F.H. Chou, C.H. Ho, and M.B. Chir Normal ranges of variability for urodynamic studies of neurogenic bladders in spinal cord injury J Spinal Cord Med 29 2006 26
19. C. Silva, J. Silva, and M.J. Ribeiro Urodynamic effect of intravesical resiniferatoxin in patients with neurogenic detrusor overactivity of spinal origin: results of a double-blind randomized placebo-controlled trial Eur Urol 48 2005 650
20. M.B. Chancellor, and W.C. de Groat Intravesical capsaicin and resiniferatoxin therapy: spicing up the ways to treat the overactive bladder J Urol 162 1999 3
21. S.A. Green, A. Alon, and J. Ianus Efficacy and safety of a neurokinin-1 receptor antagonist in postmenopausal women with overactive bladder with urge urinary incontinence J Urol 176 2006 2535
22. Data on file, Merck & Co., Inc., Rahway, New Jersey 2009.
23. J.S. Brown, K.S. McNaughton, and J.F. Wyman Measurement characteristics of a voiding diary for use by men and women with overactive bladder Urology 61 2003 802
24. S. Herschorn, S. Swift, and Z. Guan Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial BJU Int 105 2010 58
25. M. Bergstrom, R.J. Hargreaves, and H.D. Burns Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant Biol Psychiatry 55 2004 1007
26. N.R. Zinner, A. Mattiasson, and S.L. Stanton Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients J Am Geriatr Soc 50 2002 799
27. M.C. Michel, T. Schneider, and S. Krege Does gender or age affect the efficacy and safety of tolterodine? J Urol 168 2002 1027